Clinical trial
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
NCT00006007 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00006007 |
|---|---|
| Title | LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer |
| Official title | A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, pemetrexed disodium |
| Enrollment | 59 |
| Start date | Dec 1, 2000 |
| Primary completion | Mar 1, 2004 |
| Completion | May 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: